{"id":4332,"company":{"country":"US","currency":"USD","exchange":"NYSE MKT LLC","ipo":"1993-02-12","marketCap":3.312295913696289,"name":"Theriva Biologics Inc","phone":"17343327800","outstanding":17.280000686645508,"symbol":"TOVX","website":"https://therivabio.com/","industry":"Biotechnology"},"price":3.70665,"year":2024,"month":8,"day":27,"weekday":"Tuesday","title":"Impact of Technology Disruptions on Theriva Biologics Inc and Traditional Industries","date":"2024-08-27","url":"/posts/2024/08/27/TOVX","content":[{"section":"1. Innovation and Competitive Advantage","text":"Technology disruptions often bring forth innovation, allowing companies like Theriva Biologics Inc to gain a competitive advantage over traditional industry players. For example, if Theriva Biologics Inc invests in advanced biotech research and development, it could develop breakthrough treatments that outperform traditional pharmaceuticals. This could drive market share and boost the company's stock performance."},{"section":"2. Disruptive Business Models","text":"Technology disruptions can lead to the emergence of disruptive business models that challenge traditional industries. Companies like Theriva Biologics Inc may leverage technology to optimize production processes, lower costs, and deliver products and services in new and more efficient ways. This could disrupt the traditional industry supply chain and impact the stocks of companies relying on outdated business models."},{"section":"3. Market Share Shifts","text":"As technology disrupts traditional industries, market share may shift towards companies that embrace innovation. This could result in a decline in the stocks of traditional industry players who fail to adapt to changing consumer demands and technological advancements. On the other hand, companies like Theriva Biologics Inc that can successfully navigate technology disruptions may experience an increase in market share and stock performance."},{"section":"4. Workforce Changes","text":"Technology disruptions often lead to changes in the workforce requirements of traditional industries. Automation and artificial intelligence may replace certain job roles, resulting in layoffs and potential negative sentiment towards a company's stock. However, companies like Theriva Biologics Inc can proactively invest in upskilling and reskilling their workforce to align with the technology-driven landscape, mitigating any potential negative impact on stock performance."},{"section":"5. Regulatory Challenges","text":"Technology disruptions may pose regulatory challenges to traditional industries. Companies like Theriva Biologics Inc operating in highly regulated sectors such as biotech and pharmaceuticals may face increased scrutiny and compliance requirements. This could impact their ability to bring new products to market in a timely manner, potentially affecting stock performance. Therefore, it is essential for companies to proactively engage with regulators to navigate these challenges effectively."},{"section":"6. Partnerships and Collaborations","text":"In the face of technology disruptions, collaboration and partnerships with key players in the tech industry can be advantageous for both Theriva Biologics Inc and traditional industries. By leveraging the expertise and resources of technology companies, traditional industry players can enhance their competitiveness. Similarly, technology companies can gain access to existing industry knowledge and infrastructure. Such partnerships can positively impact stock performance for both parties involved."},{"section":"7. Long-Term Outlook","text":"While technology disruptions can initially cause turbulence in traditional industries, well-prepared companies like Theriva Biologics Inc can adapt and thrive in the long run. By embracing technology, investing in research and development, and staying ahead of customer needs, companies can position themselves to withstand disruptions and continue delivering value to their shareholders."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1724687483,"headline":"Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested","id":129561025,"image":"https://media.zenfs.com/en/tipranks_452/282b497649009939cb1aef102099abfe","symbol":"TOVX","publisher":"Yahoo","summary":"These are the upcoming stock splits for the week of August 26 to August 30, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In t","url":"https://finance.yahoo.com/news/upcoming-stock-splits-week-august-155123092.html"},{"category":"company","date":1724071200,"headline":"Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session","id":129444825,"image":"","symbol":"TOVX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3606107426"},{"category":"company","date":1724067360,"headline":"Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher","id":129445640,"image":"","symbol":"TOVX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3606040012"},{"category":"company","date":1724057880,"headline":"Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results","id":129443665,"image":"","symbol":"TOVX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3605882069"},{"category":"company","date":1724031600,"headline":"Nasdaq Surges 150 Points; Sonder Holdings Shares Surge","id":129446147,"image":"","symbol":"TOVX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3606171832"},{"category":"company","date":1723838700,"headline":"Theriva Biologics Announces Reverse Stock Split","id":129412451,"image":"https://media.zenfs.com/en/globenewswire.com/10937eba4dba9fa2f5389888b8ace8b9","symbol":"TOVX","publisher":"Yahoo","summary":"ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date","url":"https://finance.yahoo.com/news/theriva-biologics-announces-reverse-stock-200500387.html"},{"category":"company","date":1723778340,"headline":"Theriva biologics announces 1:25 reverse stock split","id":129423699,"image":"","symbol":"TOVX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3603483102"},{"category":"company","date":1723777620,"headline":"Theriva Biologics announces 1-for-25 reverse stock split","id":129423700,"image":"","symbol":"TOVX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3603468314"},{"category":"company","date":1723604220,"headline":"Maxim Group Remains a Buy on Theriva Biologics (TOVX)","id":129362347,"image":"","symbol":"TOVX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600650733"},{"category":"company","date":1723553880,"headline":"TOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024","id":129359582,"image":"","symbol":"TOVX","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3599036862"},{"category":"company","date":1723550982,"headline":"Theriva Biologics: Q2 Earnings Snapshot","id":129338400,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"TOVX","publisher":"Yahoo","summary":"ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Tuesday reported a loss of $8.3 million in its second quarter.","url":"https://finance.yahoo.com/news/theriva-biologics-q2-earnings-snapshot-120942059.html"},{"category":"company","date":1723550400,"headline":"Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results","id":129338403,"image":"https://media.zenfs.com/en/globenewswire.com/10937eba4dba9fa2f5389888b8ace8b9","symbol":"TOVX","publisher":"Yahoo","summary":"- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- - Received Fast Track Designation (FTD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of metastatic pancreatic adenocarcinoma- - Received Rare Pediatric Disease Designation (RPDD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatm","url":"https://finance.yahoo.com/news/theriva-biologics-reports-second-quarter-120000600.html"},{"category":"company","date":1723536000,"headline":"Theriva? Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results","id":129332194,"image":"","symbol":"TOVX","publisher":"GlobeNewswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=ef2sv73uhu"},{"category":"company","date":1723536000,"headline":"Theriva Biologics GAAP EPS of -$0.43","id":129332193,"image":"","symbol":"TOVX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598691028"},{"category":"company","date":1723533180,"headline":"Theriva Biologics reports Q2 EPS (43c), consensus (70c)","id":129332195,"image":"","symbol":"TOVX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598643843"}]}